New pill may shrink lung tumors before surgery in Gene-Mutated cancers

NCT ID NCT07156604

Not yet recruiting Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tests the drug Vebreltinib, taken as a pill for 8 weeks before surgery, in 30 people with stage IIA-IIIB non-small cell lung cancer that has a specific gene change (MET exon 14 skipping). The goal is to see if the drug can shrink tumors enough to improve surgery results. Participants will be followed for up to 3 years after surgery to monitor recurrence and survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vebreltinib (a targeted cancer pill)
What this could lead to: If successful, this could show that taking Vebreltinib before surgery helps shrink lung tumors with a specific gene change, potentially improving surgical outcomes.
What could go wrong: This is a small, early-phase trial with only 30 people, so results may not apply widely. The drug may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOADJUVANT THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOADJUVANT THERAPY NSCLC

Contacts and locations

Locations

Fudan University Shanghai Cancer Center, Shanghai,

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.